Test-firing ammunition for spliceosome inhibition in cancer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy.

Original languageEnglish (US)
Pages (from-to)6064-6066
Number of pages3
JournalClinical Cancer Research
Issue number22
StatePublished - Nov 15 2013

Fingerprint Dive into the research topics of 'Test-firing ammunition for spliceosome inhibition in cancer'. Together they form a unique fingerprint.

Cite this